Nurix Therapeutics develops small‑molecule therapies that modulate protein levels by targeting E3 ligases using its DELigase™ platform, which combines DNA‑encoded libraries with an expanding set of E3 ligases. Its leading wholly owned programs include an orally delivered BTK chimeric targeting molecule (CTM) for B‑cell malignancies and an orally delivered CBL‑B ligase inhibitor as a novel immuno‑oncology agent. The company expects to file an IND for the BTK CTM by the end of the year and is advancing the CBL‑B inhibitor through preclinical development. Proceeds from its recent financing will enable Nurix to advance these candidates into clinical development. Nurix has also formed strategic collaborations with Sanofi and Gilead that provided $100 million in upfront payments and the potential for over $4.5 billion in milestones, plus royalties and certain co‑development options. The company is headquartered in San Francisco, California. Nurix discovers and develops therapies that modulate the ubiquitin proteasome system (UPS) using a structural, mechanism-driven approach to protein–protein interactions. Its platform aims to deliver selective small-molecule drug candidates that can either promote degradation of oncogenes or protect tumor suppressors. The company emphasizes high-resolution molecular understanding of UPS components to reach targets previously inaccessible to small-molecule discovery. Nurix was founded by recognized UPS experts and is led by a management team with deep drug-discovery experience. The platform is positioned to address oncology and other disease areas by engineering ligase–substrate selectivity. The company is headquartered in San Francisco, California and is funded by Third Rock Ventures and The Column Group.

Total raised

$145M

Funding rounds

2

Latest round

Equity

Latest activity

Mar 2020